FindMyKOL
Clinical trialNCT03465592RecruitingPhase 1/PHASE2Interventional

Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

SponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrollment39SarcomaSolid Tumor, AdultSolid Tumor, Childhood
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to learn more about how the investigational drug changes blood and/or tumors. Participants are eligible for this trial if they have recently undergone a "half-matched" (haplo) bone marrow transplant and have either relapsed or are at high risk to relapse.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Johns Hopkins All Children'S Hospital

    St. Petersburg, Florida, United States

    Active, not recruiting
  • Johns Hopkins Hospital

    Baltimore, Maryland, United States

    Nicolas Llosa, MD
    Recruiting
  • Albert Einstein College of Medicine, Children'S Hospital at Montefiore

    The Bronx, New York, United States

    David Loeb, MD
    Recruiting
  • New York Medical Center/ Maria Fareri Children'S Hospital

    Valhalla, New York, United States

    Aliza Gardenswartz, MDMitchell Cario, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Nivolumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 May 2018
Primary completion
31 Jan 2027
Completion
31 Mar 2029
Last update posted
5 Feb 2026
Registered enrollment
39
Registry id
NCT03465592
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.